AR039557A1 - Inhibidores novedosos de la farnesil proteina transferasa como agentes antitumorales - Google Patents
Inhibidores novedosos de la farnesil proteina transferasa como agentes antitumoralesInfo
- Publication number
- AR039557A1 AR039557A1 ARP030100602A ARP030100602A AR039557A1 AR 039557 A1 AR039557 A1 AR 039557A1 AR P030100602 A ARP030100602 A AR P030100602A AR P030100602 A ARP030100602 A AR P030100602A AR 039557 A1 AR039557 A1 AR 039557A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- substituted
- alkyl
- arylalkyl
- different
- Prior art date
Links
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 229950008696 farnesil Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 19
- 125000001424 substituent group Chemical group 0.000 abstract 18
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 17
- 229910052799 carbon Inorganic materials 0.000 abstract 17
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 12
- 125000003118 aryl group Chemical group 0.000 abstract 11
- 150000001721 carbon Chemical group 0.000 abstract 10
- 125000001072 heteroaryl group Chemical group 0.000 abstract 10
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 10
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 150000002367 halogens Chemical class 0.000 abstract 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 7
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 7
- 125000003342 alkenyl group Chemical group 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 4
- 125000003107 substituted aryl group Chemical group 0.000 abstract 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 4
- -1 benzotriazol-1-yloxy Chemical group 0.000 abstract 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000004447 heteroarylalkenyl group Chemical group 0.000 abstract 2
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 abstract 2
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 abstract 1
- 101100294116 Caenorhabditis elegans nhr-51 gene Proteins 0.000 abstract 1
- 101100079984 Caenorhabditis elegans nhr-9 gene Proteins 0.000 abstract 1
- 102000007317 Farnesyltranstransferase Human genes 0.000 abstract 1
- 108010007508 Farnesyltranstransferase Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/085,896 US20030229099A1 (en) | 2000-08-30 | 2002-02-27 | Novel farnesyl protein transferase inhibitors as antitumor agents |
| US10/325,896 US7342016B2 (en) | 2000-08-30 | 2002-12-19 | Farnesyl protein transferase inhibitors as antitumor agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR039557A1 true AR039557A1 (es) | 2005-02-23 |
Family
ID=27767345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100602A AR039557A1 (es) | 2002-02-27 | 2003-02-25 | Inhibidores novedosos de la farnesil proteina transferasa como agentes antitumorales |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7342016B2 (enExample) |
| EP (1) | EP1492772A1 (enExample) |
| JP (1) | JP2005525356A (enExample) |
| KR (1) | KR20040098004A (enExample) |
| CN (1) | CN100537542C (enExample) |
| AR (1) | AR039557A1 (enExample) |
| AU (1) | AU2003215389B2 (enExample) |
| BR (1) | BR0308071A (enExample) |
| CA (1) | CA2477328A1 (enExample) |
| CO (1) | CO5611194A2 (enExample) |
| IL (1) | IL163673A0 (enExample) |
| MX (1) | MXPA04008303A (enExample) |
| NO (1) | NO20044053L (enExample) |
| NZ (1) | NZ534809A (enExample) |
| PE (1) | PE20031038A1 (enExample) |
| PL (1) | PL372335A1 (enExample) |
| RU (1) | RU2004128465A (enExample) |
| TW (1) | TW200303867A (enExample) |
| WO (1) | WO2003072549A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05012723A (es) * | 2003-05-30 | 2006-02-08 | Genentech Inc | Tratamiento con anticuerpos anti-vgf. |
| MXPA06001483A (es) * | 2003-08-07 | 2006-05-15 | Schering Corp | Inhibidores novedosos de la proteina farnesil transferasa como agentes antitumorales. |
| CA2568524A1 (en) * | 2004-05-28 | 2005-12-15 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| ATE412651T1 (de) | 2004-06-09 | 2008-11-15 | Glaxo Group Ltd | Pyrrolopyridinderivate |
| JP2008523148A (ja) * | 2004-12-14 | 2008-07-03 | シェーリング コーポレイション | ファルネシルプロテイントランスフェラーゼインヒビターおよび増殖性疾患を処置するための方法 |
| EP1831200A2 (en) * | 2004-12-21 | 2007-09-12 | Schering Corporation | Novel farnesyl protein transferase inhibitors as antitumor agents |
| CA2637572A1 (en) * | 2006-01-19 | 2007-07-26 | Schering Corporation | Piperazine derivatives as farnesyl protein transferase inhibitors |
| WO2008054598A2 (en) * | 2006-09-29 | 2008-05-08 | Schering Corporation | Panel of biomarkers for prediction of fti efficacy |
| KR20150097813A (ko) * | 2006-12-19 | 2015-08-26 | 제넨테크, 인크. | 조기 종양의 치료 및 아주반트 및 네오아주반트 요법을 위한 ｖｅｇｆ－특이적 길항제 |
| WO2010006432A1 (en) | 2008-07-14 | 2010-01-21 | Queen's University At Kingston | Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer |
| US8975247B2 (en) | 2009-03-18 | 2015-03-10 | The Board Of Trustees Of The Leland Stanford Junion University | Methods and compositions of treating a flaviviridae family viral infection |
| US9227962B2 (en) | 2013-03-13 | 2016-01-05 | Boston Biomedical, Inc. | Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative |
| US9187454B2 (en) * | 2013-03-13 | 2015-11-17 | Boston Biomedical, Inc. | Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof |
| CN105777646A (zh) * | 2016-04-08 | 2016-07-20 | 西南科技大学 | 一种新的5-碘-2-苯基-1-甲基咪唑的制备方法 |
| CN111454329A (zh) * | 2020-04-07 | 2020-07-28 | 哈尔滨师范大学 | 一种具有抗癌活性的异茚哚酮桥连环九肽及其制备方法 |
| CN115385892A (zh) * | 2021-10-28 | 2022-11-25 | 天津市昕晨投资发展有限公司 | 地氯雷他定衍生物、其制备方法及其用途 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5089496A (en) * | 1986-10-31 | 1992-02-18 | Schering Corporation | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies |
| US4826853A (en) | 1986-10-31 | 1989-05-02 | Schering Corporation | 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use |
| US5393890A (en) * | 1988-06-02 | 1995-02-28 | Ajinomoto Co., Inc. | Piperidine derivatives and hypotensives containing the same |
| US5416087A (en) * | 1990-10-10 | 1995-05-16 | Wong; Jesse K. | Bis-benzo, cyclohepta piperidylidene, piperidine and piperazine compounds, compositions and methods of use |
| GB9513371D0 (en) | 1995-06-30 | 1995-09-06 | Biocine Spa | Immunogenic detoxified mutant toxins |
| US5643909A (en) | 1993-04-19 | 1997-07-01 | Syntex (U.S.A.) Inc. | 10,11-Methanodibenzosuberane derivatives |
| US5719148A (en) * | 1993-10-15 | 1998-02-17 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| IL111235A (en) | 1993-10-15 | 2001-03-19 | Schering Plough Corp | Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them |
| US5721236A (en) * | 1993-10-15 | 1998-02-24 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| US6075025A (en) * | 1993-10-15 | 2000-06-13 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| US5874442A (en) * | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
| TW350844B (en) * | 1995-12-22 | 1999-01-21 | Schering Corp | Tricyclic amides useful to inhibition of G-protein function and for treatment of proliferative diseases |
| US5861395A (en) * | 1996-09-13 | 1999-01-19 | Schering Corporation | Compounds useful for inhibition of farnesyl proteins transferase |
| ATE282036T1 (de) | 1996-09-13 | 2004-11-15 | Schering Corp | Trizyklische antitumor verbindungen mit farnesyl protein transferase inhibierender wirkung |
| AU4337497A (en) * | 1996-09-13 | 1998-04-02 | Schering Corporation | Tricyclic compounds useful as fpt inhibitors |
| US6071907A (en) * | 1996-09-13 | 2000-06-06 | Schering Corporation | Tricyclic compounds useful as FPT inhibitors |
| GB9801231D0 (en) * | 1997-06-05 | 1998-03-18 | Merck & Co Inc | A method of treating cancer |
| EP0988300B1 (en) | 1997-06-17 | 2002-08-28 | Schering Corporation | Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives for the inhibition of farnesyl protein transferase |
| CA2293706C (en) | 1997-06-17 | 2008-11-18 | Schering Corporation | N-substituted urea inhibitors of farnesyl-protein transferase |
| CN1267290A (zh) | 1997-06-17 | 2000-09-20 | 先灵公司 | 新的法呢基－蛋白转移酶的三环磺酰胺抑制剂 |
| ZA985203B (en) | 1997-06-17 | 1999-01-05 | Schering Corp | Compounds useful for inhibition of farnesyl protein transferase |
| US5925648A (en) * | 1997-07-29 | 1999-07-20 | Schering Corporation | Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase |
| HUP0202152A2 (en) | 1998-12-18 | 2002-10-28 | Schering Corp | Tricyclyc farnesyl protein transferase inhibitors |
| IL143409A0 (en) | 1998-12-18 | 2002-04-21 | Schering Corp | Farnesyl protein transferase inhibitors |
| AU2292801A (en) * | 1999-12-22 | 2001-07-03 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Compositions and methods for treatment of breast cancer |
| JP5491681B2 (ja) | 2000-02-04 | 2014-05-14 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 乳ガンの治療のためのファルネシルタンパク質トランスフェラーゼ阻害剤 |
| AR033680A1 (es) * | 2000-08-30 | 2004-01-07 | Schering Corp | Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales |
| EP1453513A1 (en) * | 2001-12-03 | 2004-09-08 | Schering Corporation | Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer |
| MXPA06001483A (es) * | 2003-08-07 | 2006-05-15 | Schering Corp | Inhibidores novedosos de la proteina farnesil transferasa como agentes antitumorales. |
-
2002
- 2002-12-19 US US10/325,896 patent/US7342016B2/en not_active Expired - Fee Related
-
2003
- 2003-02-25 EP EP03711214A patent/EP1492772A1/en not_active Withdrawn
- 2003-02-25 CN CNB038047209A patent/CN100537542C/zh not_active Expired - Fee Related
- 2003-02-25 IL IL16367303A patent/IL163673A0/xx unknown
- 2003-02-25 CA CA002477328A patent/CA2477328A1/en not_active Abandoned
- 2003-02-25 BR BR0308071-4A patent/BR0308071A/pt not_active IP Right Cessation
- 2003-02-25 MX MXPA04008303A patent/MXPA04008303A/es unknown
- 2003-02-25 WO PCT/US2003/005479 patent/WO2003072549A1/en not_active Ceased
- 2003-02-25 RU RU2004128465/04A patent/RU2004128465A/ru not_active Application Discontinuation
- 2003-02-25 JP JP2003571255A patent/JP2005525356A/ja active Pending
- 2003-02-25 NZ NZ534809A patent/NZ534809A/en not_active IP Right Cessation
- 2003-02-25 KR KR10-2004-7013310A patent/KR20040098004A/ko not_active Abandoned
- 2003-02-25 PL PL03372335A patent/PL372335A1/xx not_active Application Discontinuation
- 2003-02-25 AR ARP030100602A patent/AR039557A1/es unknown
- 2003-02-25 AU AU2003215389A patent/AU2003215389B2/en not_active Ceased
- 2003-02-26 TW TW092104046A patent/TW200303867A/zh unknown
- 2003-02-26 PE PE2003000190A patent/PE20031038A1/es not_active Application Discontinuation
-
2004
- 2004-08-13 CO CO04079404A patent/CO5611194A2/es not_active Application Discontinuation
- 2004-09-24 NO NO20044053A patent/NO20044053L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2004128465A (ru) | 2005-09-27 |
| NO20044053L (no) | 2004-11-26 |
| US7342016B2 (en) | 2008-03-11 |
| BR0308071A (pt) | 2004-12-21 |
| PE20031038A1 (es) | 2004-01-10 |
| EP1492772A1 (en) | 2005-01-05 |
| CN100537542C (zh) | 2009-09-09 |
| AU2003215389A1 (en) | 2003-09-09 |
| JP2005525356A (ja) | 2005-08-25 |
| NZ534809A (en) | 2007-12-21 |
| US20040122018A1 (en) | 2004-06-24 |
| PL372335A1 (en) | 2005-07-11 |
| AU2003215389B2 (en) | 2007-10-18 |
| CO5611194A2 (es) | 2006-02-28 |
| IL163673A0 (en) | 2005-12-18 |
| KR20040098004A (ko) | 2004-11-18 |
| CN1630641A (zh) | 2005-06-22 |
| MXPA04008303A (es) | 2005-11-23 |
| CA2477328A1 (en) | 2003-09-04 |
| WO2003072549A1 (en) | 2003-09-04 |
| TW200303867A (en) | 2003-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR039557A1 (es) | Inhibidores novedosos de la farnesil proteina transferasa como agentes antitumorales | |
| PE20170247A1 (es) | Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1 | |
| ECSP077417A (es) | Nuevos derivados de aminopiridina que tienen acción inhibitoria selectiva de la aurora a | |
| PE20220567A1 (es) | Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR033680A1 (es) | Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales | |
| AR044629A1 (es) | Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos. | |
| AR043190A1 (es) | Derivados de quinoleina como inhibidores del factor inhibidor de la migracion de macrofagos y metodos para su identificacion. sintesis y composiciones farmaceuticas. | |
| CO6241101A2 (es) | Derivados de quinolina como inhibidores de la p13 quinasa | |
| HUP9901590A2 (hu) | Szubsztituált aza- és diaza-cikloheptán- és -ciklooktán-származékok, alkalmazásuk, a vegyületeket tartalmazó gyógyászati készítmények | |
| RU2012140961A (ru) | ПРОИЗВОДНОЕ 1,3,4,8-ТЕТРАГИДРО-2Н-ПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНИБИТОРА ИНТЕГРАЗЫ ВИЧ | |
| AR046711A1 (es) | 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones | |
| AR057626A1 (es) | Derivados de pirido pirazo y pirimido- pirimidina y su uso como inhibidores de mtor | |
| AR099363A1 (es) | Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil y pirrolo[2,3-d]piridinil acrilamidas | |
| ES2668826T3 (es) | Lípidos, complejos lipídicos y uso de los mismos | |
| EA201171328A1 (ru) | Производное замещенного изохинолина | |
| PE20160501A1 (es) | Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih | |
| AR039665A1 (es) | Fenilacetamidas sustituidas y su uso como activadores de glucoquinasa | |
| BRPI0718966B8 (pt) | composto, composição farmacêutica, inibidor plk1 e agente antitumoral | |
| AR090328A1 (es) | Pirrolidina-2-carboxamidas sustituidas | |
| AR047848A1 (es) | Analogos de rifamicina y composiciones farmaceuticas que los contienen. | |
| AR081757A1 (es) | Compuestos cefem que contienen seudocatecol | |
| AR036248A1 (es) | Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica | |
| ES2626801T3 (es) | Compuestos de triazolopiridina como inhibidores de pde10a | |
| UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| AR043487A1 (es) | Heterociclos fusionados de pirimidina y usos de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |